SOURCE: WayPoint Biomedical, Inc.

October 31, 2005 16:15 ET

WayPoint Biomedical's Drink Detective™ Featured in Canada's Leading Newspaper, the "Toronto Sun" -- Sunday Edition "Life" Section, as Lead Article on Date-Rape

HUNTINGTON BEACH, CA -- (MARKET WIRE) -- October 31, 2005 -- WayPoint Biomedical, Inc. (OTC: WYPB) had their flagship product, the Drink Detective™, featured in a front page article for the "Life" section of last Sunday's (October 23rd) Toronto Sun newspaper. Written by Valerie Gibson, the lead piece is titled "Dodging the Date Rape - Preventative Action is About to Arrive in Canada - It's the Drink Detective™." The Sunday edition of the Toronto Sun has a loyal following and boasts an average total weekly readership of over 900,000 subscribers.

The editorial begins by relaying the tragic story of a young Canadian lady who, after having her drink spiked, quickly becomes incapacitated -- lapsing in and out of consciousness -- she ends up being brutally raped by two different men in one evening. Ms. Gibson's article then goes on to provide tips on How to Drink Safely, How to Get Help, Where to Get Help, and finishes by providing useful information on WayPoint's Drink Detective™ product, drink spiking & date-rape awareness campaign (www.drinkdetectiveusa.com).

In addition to informative tips about the credit card-sized test and how it is to be used, the article informs readers that, "The Drink Detective™ will be available widely at stores including the LCBO, Shoppers Drug Mart, Pharma Plus, grocery and gas station stores." With over 25,000 potential retail outlets, WayPoint projects first-year Canadian sales to potentially be in excess of $1,000,000.

About WayPoint Biomedical:

WayPoint Biomedical, Inc., a wholly owned subsidiary of WayPoint Biomedical Holdings, Inc. (OTC: WYPB), is an innovative biomedical technology firm, specializing in diagnostic tests and devices for screening and monitoring human health, fitness and environment. The Company develops and markets cutting-edge disposable rapid tests that offer both a preliminary diagnostic screen to specific conditions, along with a future path for consumers, medical providers, and first responders to follow regarding their health status or environmental condition. WayPoint's unique and affordable home-based and on-site tests are focused on detecting the cause of a disease or pathogen, as opposed to determining the symptom; becoming a part of the solution to help reverse the escalating cost of Healthcare. The Company's primary target sectors are the Over the Counter (OTC) Self-Testing Market, the Diagnostic Point of Care (POC) Testing Market, and the Homeland Security & Defense Market, three of the fastest-growing areas in all of diagnostic medicine and science. For more information on WayPoint Biomedical visit www.waypointbiomedical.com, www.drinkdetectiveusa.com.

Included in this release are certain "forward-looking'' statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding WayPoint's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to WayPoint's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. WayPoint Biomedical does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.

Contact Information